Kelvin Caban

Kelvin Caban Ph.D. is a Principal Scientist at PTC Therapeutics, Inc., with extensive experience in advancing small molecules to the hit-to-lead stage, developing screening programs using DNA-encoded libraries, and implementing innovative target-degradation modalities. Prior roles include Senior Scientist and Scientist-II at PTC Therapeutics, where significant contributions involved high-throughput screening and molecular target identification. Kelvin's research background includes an Associate Research Scientist and postdoctoral position at Columbia University, focusing on ribosomal subunit joining in protein synthesis, as well as a Ph.D. from Rutgers Robert Wood Johnson Medical School, where work centered on selenocysteine incorporation in protein synthesis. Kelvin holds a Bachelor's degree in Molecular Biology from Montclair State University.